Momenta (MNTA) has impressively transformed its self rather quickly from a company developing biosimilars and complex generics to a company developing novel medications. It currently has a few drugs in clinical development. The company’s future will mostly be driven by the success or failure of these of drugs.
Before we jump to the new medications under development, a quick recap of Momenta’s legacy business that consists of biosimilars and generics. This legacy business still generates a modest amount of revenue. Glatopa, is a generic version of Teva’s Copaxone. I once thought Glatopa was going to